BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial

NCT03702608 NA COMPLETED Results posted

This is a prospective, multi-center, single-arm, open-label clinical trial. Clinical follow-up will be performed at 30 days. Follow-up by phone will be performed at 6 months, and 1 year after the procedure. Study Objective is to further assess the safety and efficacy of long (38 mm) Ridaforolimus Eluting Stent - EluNIR.

Details

Lead sponsor	Medinol Ltd.
Phase	NA
Status	COMPLETED
Enrolment	50
Start date	Wed Nov 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Apr 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Coronary Stenosis

Interventions

• EluNIR Ridaforolimus Eluting Coronary Stent System

Countries

Israel